06.10.16
Averica Discovery Services, an analytical development contract research organization (CRO), and Dalton Pharma Services, a contract provider of integrated chemistry, drug development, and manufacturing services, have entered a preferred provider agreement involving advanced analytical services.
The agreement leverages the strengths of both companies in order to enhance client pharmaceutical development programs. Averica provides specialized expertise in impurity isolation, small molecule analysis and purification. Dalton is a full service contract provider with a strong focus on active pharmaceutical ingredient (API) development and cGMP manufacturing. Averica’s capabilities will expand Dalton’s capacity and allow faster validation of assay, impurities, and release testing methods. The key expertise of Averica in impurity isolation can also improve timelines for Dalton’s clinical and commercial cGMP synthesis.
“We are very pleased to have established and qualified Averica as a trusted partner,” said Peter Pekos, chief executive officer and president, Dalton Pharma Services. “Averica and Dalton are premium contract vendors known for a culture of excellence and the ability to deal with technically challenging compounds.”
Jeffrey Kiplinger, president, Averica, said, “This agreement establishes a collaborative strategy that aims to accelerate project timelines. We are grateful to be recognized as a valued Dalton partner by virtue of our unique capabilities.”
The agreement leverages the strengths of both companies in order to enhance client pharmaceutical development programs. Averica provides specialized expertise in impurity isolation, small molecule analysis and purification. Dalton is a full service contract provider with a strong focus on active pharmaceutical ingredient (API) development and cGMP manufacturing. Averica’s capabilities will expand Dalton’s capacity and allow faster validation of assay, impurities, and release testing methods. The key expertise of Averica in impurity isolation can also improve timelines for Dalton’s clinical and commercial cGMP synthesis.
“We are very pleased to have established and qualified Averica as a trusted partner,” said Peter Pekos, chief executive officer and president, Dalton Pharma Services. “Averica and Dalton are premium contract vendors known for a culture of excellence and the ability to deal with technically challenging compounds.”
Jeffrey Kiplinger, president, Averica, said, “This agreement establishes a collaborative strategy that aims to accelerate project timelines. We are grateful to be recognized as a valued Dalton partner by virtue of our unique capabilities.”
